[Hiring] Medical Science Liaison @Aveo Oncology

Role Description

The Medical Science Liaison is a trusted partner to key external experts by conducting timely, compliant, and frequent scientific exchanges to enhance the understanding of the scientific and medical value of our products. The incumbent MSL will have demonstrated ability to execute on stakeholder engagement plans to gather data, develop and share medical insights that contribute to the enhancement of AVEO Oncology key medical messages and plans for future research. Excellent interpersonal communication and presentation skills are critical as is an organized approach to prioritization of responsibilities and deliverables. A flexible and adaptable work style, an openness to creativity and ability to work in a team environment with our cross-functional partners is essential.

• Identifies, builds and maintains solid relationships with relevant oncology KOLs
• Presents clinical data to appropriate audiences in a compliant manner
• Performs therapeutic disease state education in oncology with identified physicians and researchers, Pharm Ds, nurse practitioners, nurses and other health care professionals
• Provide ongoing field updates and insights, including competitive intelligence, and synthesize this information into meaningful, actionable imperatives
• Attends various scientific conferences to collect and report relevant scientific and clinical data
• Communication of scientific and clinical data through presentations, (adboards and other forums) abstracts and posters
• Participates in the development and management of oncology clinical trials
• Identifies and assists in selection of investigators and oncology clinical trial sites
• Support speakers training to ensure continued scientific support in the field (after working cross functionally)
• Responds to unsolicited request for medical information associated with supported products and disease state area
• Provide medical support and expertise to cross-functional partners (Marketing, Training, Market Access, Clinical Development)
• Participate in the development and execution of Medical Affairs activities, such Advisory Boards, and development of scientific and medical presentation slides
• Develop and maintain scientific, clinical and therapeutic expertise in relevant disease states; and deliver medical presentations to both internal and external stakeholders
• Demonstrate the ability and desire to work collaboratively, respectfully, and creatively with diverse stakeholders, including leadership within the MSL team
• Other responsibilities as business required and assigned
• Ability to travel for business - Estimated travel ~40-60%

Qualifications

• Advanced health care degree required (MD or DO, PhD, PharmD, RN), doctoral degree preferred
• Minimum of 6+ years of experience as an MSL in oncology (RCC experience highly desirable); product launch experience preferred
• A well-established KOL hematology/oncology network is strongly preferred
• Proven track record of success in establishing and maintaining thought leader relationships, territory planning, and integration with other field roles
• Experience working with Thought Leader Engagement (TLE) teams
• Strong understanding of industry and regulatory guidelines pertinent to compliant interactions with external audiences
• Demonstrated ability to comprehend complex scientific, medical, and relevant business issues and respond with actionable strategies and tactics to effectively produce timely and measurable results
• Strong interpersonal and communication skills, both oral and written
• Excellent ability in searching and interpreting medical literature
• Technical aptitude for virtual meetings and virtual conferences
• Flexibility to work outside of standard working hours on an as needed basis

Company Description

AVEO is a commercial-stage, oncology-focused biopharmaceutical company committed to delivering medicines that provide a better life for patients with cancer. AVEO currently markets FOTIVDA® (tivozanib) in the U.S. for the treatment of adult patients with relapsed or refractory renal cell carcinoma (RCC) following two or more prior systemic therapies. AVEO continues to develop FOTIVDA in immuno-oncology combinations in RCC and other indications and has several other investigational programs in clinical development. AVEO is committed to creating an environment of diversity, equity and inclusion to diversify representation within the Company.